Experienced in Melanoma

Dr. Ralph G. Zinner

Oncology
Kentucky Medical Services Foundation, Inc
800 Rose St, 
Lexington, KY 
Clinical Trials:Currently Recruiting for 2 Trials
Offers Telehealth
Experienced in Melanoma
Kentucky Medical Services Foundation, Inc
800 Rose St, 
Lexington, KY 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Ralph Zinner is an Oncologist in Lexington, Kentucky. Dr. Zinner is rated as an Experienced provider by MediFind in the treatment of Melanoma. His top areas of expertise are Non-Small Cell Lung Cancer (NSCLC), Small Cell Lung Cancer (SCLC), ALK-Positive Non-Small Cell Lung Cancer, and Squamous Cell Lung Carcinoma.

His clinical research consists of co-authoring 82 peer reviewed articles and participating in 10 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 6 articles and participated in 1 clinical trial in the study of Melanoma.

Specialties
Oncology
Licenses
Internal Medicine in KY
Hospital Affiliations
University Of Kentucky Hospital
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
CareSource
  • HMO
Cigna
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 5 Less Insurance Carriers -

Locations

KENTUCKY MEDICAL SERVICES FOUNDATION, INC
800 Rose St, Lexington, KY 40536

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

10 Clinical Trials

LUNGMAP: A Master Protocol To Evaluate Biomarker-Driven Therapies And Immunotherapies In Previously-Treated Non-Small Cell Lung Cancer (Lung-Map Screening Study)
LUNGMAP: A Master Protocol To Evaluate Biomarker-Driven Therapies And Immunotherapies In Previously-Treated Non-Small Cell Lung Cancer (Lung-Map Screening Study)
Enrollment Status: Recruiting
Publish Date: March 13, 2025
Intervention Type: Drug
Study Drug: Screening Platform
Study Phase: Phase 2/Phase 3
A Randomized Phase III Trial for Surgically Resected Early Stage Non-small Cell Lung Cancer: Crizotinib Versus Observation for Patients With Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein
A Randomized Phase III Trial for Surgically Resected Early Stage Non-small Cell Lung Cancer: Crizotinib Versus Observation for Patients With Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein
Enrollment Status: Recruiting
Publish Date: July 03, 2024
Intervention Type: Other, Drug
Study Drug: Crizotinib
Study Phase: Phase 3
Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)
Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)
Enrollment Status: Active_not_recruiting
Publish Date: October 06, 2025
Intervention Type: Other, Procedure, Biological, Drug
Study Phase: Not Applicable
Randomized Study of Erlotinib Vs Observation in Patients With Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer (NSCLC)
Randomized Study of Erlotinib Vs Observation in Patients With Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer (NSCLC)
Enrollment Status: Active_not_recruiting
Publish Date: September 22, 2025
Intervention Type: Other, Drug
Study Drug: Erlotinib Hydrochloride
Study Phase: Phase 3
Adjuvant Nivolumab in Resected Lung Cancers (ANVIL)-A Randomized Phase III Study of Nivolumab After Surgical Resection and Adjuvant Chemotherapy in Non-Small Cell Lung Cancers
Adjuvant Nivolumab in Resected Lung Cancers (ANVIL)-A Randomized Phase III Study of Nivolumab After Surgical Resection and Adjuvant Chemotherapy in Non-Small Cell Lung Cancers
Enrollment Status: Active_not_recruiting
Publish Date: September 22, 2025
Intervention Type: Procedure, Biological, Other
Study Drug: Nivolumab
Study Phase: Phase 3
An Open-Label Phase 1/2 Study of Itacitinib in Combination With Osimertinib in Subjects With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
An Open-Label Phase 1/2 Study of Itacitinib in Combination With Osimertinib in Subjects With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Enrollment Status: Active_not_recruiting
Publish Date: July 04, 2025
Intervention Type: Drug
Study Drugs: Itacitinib, Osimertinib
Study Phase: Phase 1/Phase 2
A Phase II Study of Rucaparib in Patients With Genomic LOH High and/or Deleterious BRCA1/2 Mutation Stage IV or Recurrent Non-Small Cell Lung Cancer (LUNG-MAP Sub-Study)
A Phase II Study of Rucaparib in Patients With Genomic LOH High and/or Deleterious BRCA1/2 Mutation Stage IV or Recurrent Non-Small Cell Lung Cancer (LUNG-MAP Sub-Study)
Enrollment Status: Completed
Publish Date: May 21, 2025
Intervention Type: Drug
Study Drug: Rucaparib
Study Phase: Phase 2
An Exploratory Study to Investigate the Immunomodulatory Activity of Radiation Therapy (RT) in Combination With MK-3475 in Patients With Recurrent/Metastatic Head and Neck, Renal Cell Cancer, Melanoma and Lung Cancer
An Exploratory Study to Investigate the Immunomodulatory Activity of Radiation Therapy (RT) in Combination With MK-3475 in Patients With Recurrent/Metastatic Head and Neck, Renal Cell Cancer, Melanoma and Lung Cancer
Enrollment Status: Completed
Publish Date: May 15, 2025
Intervention Type: Radiation, Drug
Study Drug: MK-3475
Study Phase: Phase 1
Nivolumab Plus Weekly Carboplatin and Paclitaxel as Induction in Resectable Locally Advanced Head and Neck Cancer
Nivolumab Plus Weekly Carboplatin and Paclitaxel as Induction in Resectable Locally Advanced Head and Neck Cancer
Enrollment Status: Completed
Publish Date: April 24, 2025
Intervention Type: Biological, Drug
Study Phase: Phase 2
Nivolumab Plus Cisplatin/Pemetrexed or Cisplatin/Gemcitabine as Induction in Resectable Non-Small Cell Lung Cancer
Nivolumab Plus Cisplatin/Pemetrexed or Cisplatin/Gemcitabine as Induction in Resectable Non-Small Cell Lung Cancer
Enrollment Status: Completed
Publish Date: April 03, 2023
Intervention Type: Drug, Biological
Study Drugs: Nivolumab, Cisplatin, Pemetrexed Disodium, Gemcitabine Hydrochloride
Study Phase: Phase 2
View 8 Less Clinical Trials

82 Total Publications

L858R/L718Q and L858R/L792H Mutations of EGFR Inducing Resistance Against Osimertinib by Forming Additional Hydrogen Bonds.
L858R/L718Q and L858R/L792H Mutations of EGFR Inducing Resistance Against Osimertinib by Forming Additional Hydrogen Bonds.
Journal: Proteins
Published: July 16, 2024
Similar Doctors
Advanced in Melanoma
Dr. Frederick R. Ueland
Gynecologic Oncology | Obstetrics and Gynecology | Oncology
Advanced in Melanoma
Dr. Frederick R. Ueland
Gynecologic Oncology | Obstetrics and Gynecology | Oncology

Kentucky Medical Services Foundation, Inc

2400 Greatstone Pt, 
Lexington, KY 
 (2.4 miles away)
859-323-7426
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Frederick Ueland is a Gynecologic Oncologist and an Obstetrics and Gynecologist in Lexington, Kentucky. Dr. Ueland is rated as a Distinguished provider by MediFind in the treatment of Melanoma. His top areas of expertise are Ovarian Cancer, Endometrial Cancer, Vulvar Cancer, Hysterectomy, and Oophorectomy. Dr. Ueland is currently accepting new patients.

Advanced in Melanoma
Dr. Christopher P. Desimone
Gynecologic Oncology | Oncology | Obstetrics and Gynecology
Advanced in Melanoma
Dr. Christopher P. Desimone
Gynecologic Oncology | Oncology | Obstetrics and Gynecology

Kentucky Medical Services Foundation, Inc

800 Rose St, 
Lexington, KY 
 (0.1 miles away)
859-323-5000
Languages Spoken:
English
See accepted insurances

Christopher Desimone is a Gynecologic Oncologist and an Oncologist in Lexington, Kentucky. Dr. Desimone is rated as an Advanced provider by MediFind in the treatment of Melanoma. His top areas of expertise are Vulvar Cancer, Ovarian Cancer, Melanoma, Oophorectomy, and Hernia Surgery.

Rebecca A. Redman
Advanced in Melanoma
Dr. Rebecca A. Redman
Hematology Oncology | Hematology | Oncology
Advanced in Melanoma
Dr. Rebecca A. Redman
Hematology Oncology | Hematology | Oncology

University Of Louisville Physicians Inc

2401 Terra Crossing Blvd, 
Louisville, KY 
 (56.2 miles away)
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Rebecca Redman is a Hematologist Oncology specialist and a Hematologist in Louisville, Kentucky. Dr. Redman is rated as a Distinguished provider by MediFind in the treatment of Melanoma. Her top areas of expertise are Merkel Cell Carcinoma, Laryngeal Cancer, Throat Cancer, and Familial Colorectal Cancer. Dr. Redman is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Zinner's expertise for a condition
ConditionClose
    View All 9 Distinguished Conditions
      View All 17 Experienced Conditions
      Want to save this doctor for later?
      Sign Up
      Is this your doctor?
      Find A Second Opinion
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile